REVB - Revelation Biosciences Inc Profile, Share Price, Market Analysis, Charts, Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Revelation Biosciences Inc   (NASDAQ: REVB)
 
Price: $0.9985 $0.00 -0.050%
Day's High: $0.9994999766349792 Week Perf: -1.14 %
Day's Low: $ 0.99 30 Day Perf: -10.05 %
Volume (M): 2,739 52 Wk High: $ 7.60
Volume (M$): $ 0 52 Wk Avg: $2.36
Open: $1.00 52 Wk Low: $0.88



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 4
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Business Description


Revelation Biosciences Inc is a biotechnology company that focuses on the development of innovative therapies for various diseases. The company specializes in the discovery and development of small molecule drugs and biologics targeting a range of therapeutic areas, including inflammation, immunology, and oncology. They employ state-of-the-art technologies and a multidisciplinary approach to accelerate the development of novel treatments. Revelation Biosciences aims to address the unmet medical needs of patients through their research and discovery efforts.


   Company Address: 4660 La Jolla Village Drive San Diego 92122 CA
   Company Phone Number: 800-3717   Stock Exchange / Ticker: NASDAQ REVB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.43%    
ACRV   -5.34%    
ALT        2.01% 
ANIX   -6.89%    
APVO        11.01% 
CYPH   -0.22%    
• View Complete Report
   



Business Update

Strategic Maneuver Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split to Optimize Market Position

Published Sat, Jan 25 2025 4:43 PM UTC

: Revelation Biosciences Inc. a player in the biopharmaceutical sector, has announced a significant corporate decision to implement a 1-for-16 reverse stock split, effective January 28, 2025. This strategic move comes after approval from the company s Special Meeting of Stockholders on January 17, 2025. The necessity for this action arises within the context of the companyâ...
Business Update

Strategic Financial Restructuring Revelation Biosciences Implements a 1-for-16 Reverse Stock Split

Published Sat, Jan 25 2025 8:23 AM UTC

In a significant development illustrating the company s commitment to enhancing shareholder value and financial positioning, Revelation Biosciences Inc. (NASDAQ: REVB) has announced a 1-for-16 reverse stock split effective January 28, 2025. This decision follows the approval granted during the Special Meeting of Stockholders held on January 17, 2025, signaling a transformati...
Business Update

Revelation Biosciences Gemini IND Accepted by FDA Amidst Competitive Revenue Struggles

Published Mon, Dec 2 2024 12:05 PM UTC

Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences company focused on leveraging trained immunity for the treatment of various diseases, recently announced a significant milestone with the acceptance of its investigational new drug (IND) application for Gemini by the United States Food and Drug Administration (FDA). This acceptance enables the compan...
Stocks on the Move

The Upward Surge of Revelation Biosciences Inc A Promising Turnaround for Investors

Published Tue, Jun 25 2024 11:56 AM UTC

Investing in the stock market can be a rollercoaster ride with unpredictable outcomes. This year, Revelation Biosciences Inc has faced challenges in meeting investor expectations, trailing behind the market s performance. However, recent events suggest a promising turnaround for the company, igniting excitement among investors. In this article, we will examine the events sur...
Product Service News

Harnessing the Power of Trained Immunity: Promising Preclinical Data on Gemini's Potential Therapeutic Benefit for Acute Kidney Injury Prevention

Published Wed, Mar 13 2024 1:00 PM UTC

Revelation Biosciences Inc. is a clinical-stage life sciences company at the forefront of harnessing trained immunity for the prevention and treatment of diseases. Recently, they presented new preclinical data on the potential therapeutic benefit of their innovative product Gemini for the prevention of acute kidney injury (AKI) at the International Conference on Advances in ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.38
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.11
Working Capital Ratio 6.21
Leverage Ratio (MRQ) 0.24
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -14.52 $
Revenues (TTM) -
Cash Flow (TTM) 2.33 $
Cash 3 $
Book Value 2.63 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,133,553
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.